6.Ruggenenti P1, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012 Dec;23(12):1917-28. http://www.ncbi.nlm.nih.gov/pubmed/23100218
7.Nawaz FA1, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 2013 Nov;62(5):1012-7. http://www.ncbi.nlm.nih.gov/pubmed/23773370
8.Stuard S, Belcaro G, Cesarone MR, et al. Kidney function in metabolic syndrome may be improved with Pycnogenol®. Panminerva Med. 2010 Jun;52(2 Suppl 1):27-32. http://www.ncbi.nlm.nih.gov/pubmed/20657531
9.Cesarone MR, Belcaro G, et al. Kidney Flow and Function in Hypertension: Protective Effects of Pycnogenol in Hypertensive Participants—A Controlled Study. J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):41-6. http://www.ncbi.nlm.nih.gov/pubmed/20097689